[ad_1]
NEW YORK (Reuters Health) – A recently approved drug has been shown to be very effective in treating a type of leukemia, a B-cell lymphoma, according to a recent US study.
The study was conducted by researchers at the MD Anderson Cancer Center of the University of Texas, Texas, and presented its findings Monday at the annual conference on hematology, to be held from 1 December 4 in San Diego.
The team studied the effectiveness of Axi-cel, which was approved by the US Food and Drug Administration in October 2017 and by the European Commission in August 2018 for the treatment of lymphoma.
In a study of 27 patients with 27-month large-cell lymphoma, the results showed that 51% of patients who received the new drug survived another two years after the start of treatment.
The researchers found that 83% of patients achieved a reduction in cancer-related activity, called objective response, while the full response rate of treatment was 58%.
The new main treatment idea is to extract the immune cells from the patient's body and reconfigure their genes so that they only attack the tumor, then return them to the body to do the work and remove the tumor. Cancer.
Lymphoma is a type of cancer of the blood and bone marrow, a spongy tissue in the bone that makes blood cells.
The term "lymphoid" in lymphocytic leukemia comes from cells affected by the disease, a group of white blood cells called lymphocytes, which help the body fight off infections.
Lymphoma, a cancer of the lymph glands, is a cancerous tumor that affects the cells of the lymphatic system and causes many symptoms, including fatigue, exhaustion, high fever, sweating and lymph nodes.
The National Cancer Institute estimated that about 72,000 people in the United States had been diagnosed with lymphoma in 2017.
Source link
